Every aesthetic laser, RF microneedling device, IPL platform, and ultrasound skin-tightening system for sale in the United States passed through the FDA before reaching a clinic. But the path they took — and the words the FDA uses to describe it — are widely misunderstood.
The distinction matters. "FDA cleared," "FDA approved," and "FDA registered" mean different things, carry different evidentiary thresholds, and have different implications for patient safety. If you are a patient choosing a clinic, a provider evaluating a new device, or a practice owner deciding whether to invest $50,000–$250,000 in a platform, understanding how the FDA actually evaluates aesthetic devices changes how you read marketing claims.
What the FDA Regulates in Aesthetics
The FDA's Center for Devices and Radiological Health (CDRH) regulates medical devices, which include aesthetic energy-based devices such as:
- Lasers — CO₂ fractional, erbium:YAG, alexandrite, Nd:YAG, diode, picosecond, and KTP
- Intense pulsed light (IPL) and broadband light (BBL)
- Radiofrequency (RF) devices — RF microneedling (Morpheus8, Sylfirm X, Secret RF), monopolar RF (Thermage), and bipolar RF platforms
- Ultrasound devices — Ultherapy / Ultherapy PRIME, Sofwave
- Electromagnetic muscle stimulation — Emsculpt Neo, truFlex
- Cryolipolysis — CoolSculpting
Injectable products like Botox, Juvéderm, and Sculptra follow a different regulatory path — they are regulated as drugs or biologics and require Premarket Approval (PMA) or Biologics License Applications (BLA), which involve full clinical trials. Devices, by contrast, almost always enter the market through the 510(k) pathway.
Device Classes: I, II, and III
The FDA assigns medical devices to one of three risk classes:
| Class | Risk Level | Typical Aesthetic Examples | Regulatory Pathway |
|---|---|---|---|
| Class I | Low | Manual dermal rollers (non-powered microneedling), some topical applicators | General controls; most are 510(k)-exempt |
| Class II | Moderate | Lasers, IPL, RF microneedling, ultrasound, cryolipolysis | 510(k) clearance (most common) |
| Class III | High | Implantable devices, combination products | Premarket Approval (PMA) |
Nearly every energy-based device used in aesthetic clinics is Class II. That classification triggers the 510(k) requirement.
How the 510(k) Pathway Works
The 510(k) pathway — formally called a Premarket Notification — is built on the concept of substantial equivalence. A manufacturer does not need to prove their device is safe and effective through independent clinical trials. Instead, they must demonstrate that it is "substantially equivalent" to a predicate device already legally on the market.
What "substantially equivalent" means
The FDA finds a device substantially equivalent if:
- It has the same intended use as the predicate device, and
- It either has the same technological characteristics, or has different technological characteristics that do not raise new questions of safety and effectiveness — and the manufacturer can show it is at least as safe and effective as the predicate.
This is a comparison standard, not an independent safety-and-effectiveness standard. The FDA is not examining whether the device is safe for patients in isolation. It is agreeing with the manufacturer's claim that the device is similar enough to something already cleared.
The 510(k) process steps
Identify a predicate device. The manufacturer searches the FDA's 510(k) database for a legally marketed device with a similar intended use and technological profile.
Prepare the submission. The package includes device description, intended use statement, comparison to the predicate, performance data (often bench testing, sometimes clinical), labeling, and software documentation. Since early 2026, the new Quality Management System Regulation (QMSR) — aligned with ISO 13485:2016 — also applies.
Submit and pay the user fee. The FY 2025 user fee is $24,335 for standard businesses and $6,084 for small businesses (those with under $100 million in annual revenue). Submissions are now electronic, using the FDA's eSTAR template.
FDA review. The target is 90 FDA review days. In practice, the average in recent years has been closer to 108–163 days when you include requests for additional information. About 95% of 510(k) submissions that go to decision receive a "substantially equivalent" (SE) determination.
Clearance letter. If the FDA agrees the device is substantially equivalent, the manufacturer receives an SE letter and may begin marketing the device in the United States.
Post-clearance obligations. Within 30 days, the manufacturer must register their establishment and list the newly cleared device. Ongoing compliance with the QMSR, adverse event reporting (MedWatch), and post-market surveillance applies.
"Cleared" vs. "Approved" vs. "Registered"
These terms are not interchangeable. Using the wrong one in marketing is an FDA enforcement trigger.
| Term | What It Means | Pathway | Evidence Standard |
|---|---|---|---|
| FDA Cleared | The device is substantially equivalent to a predicate already on the market | 510(k) | Comparative; no independent clinical trials required |
| FDA Approved | The FDA has determined the device is safe and effective based on its own review of clinical data | PMA | Full clinical evidence; typically Class III devices |
| De Novo Granted | The device is novel (no predicate) but low-to-moderate risk; creates a new classification | De Novo | Evidence of safety and effectiveness, but less than PMA |
| FDA Registered | The manufacturer has listed the device with the FDA | Registration only | No review of safety or effectiveness |
Most aesthetic devices are cleared, not approved. A clinic advertising "FDA-approved laser treatment" is making an inaccurate claim. The correct language is "FDA-cleared."
The De Novo Pathway — When There Is No Predicate
When a device is genuinely novel and no predicate exists, the manufacturer can use the De Novo classification pathway. This was the route microneedling devices initially took: the first microneedling device went through De Novo, creating a new device classification. Subsequent microneedling devices then entered through 510(k), citing the De Novo-granted device as their predicate.
De Novo requires the manufacturer to provide evidence of safety and effectiveness — more than a 510(k), but less than a PMA. The FY 2025 user fee is $162,235 ($40,559 for small businesses), and the target review time is 150 FDA days.
What 510(k) Clearance Does — and Does Not — Guarantee
Understanding the limits of the 510(k) process is critical for both providers and patients.
What it guarantees
- The device has the same intended use as a predicate already on the market
- Any technological differences do not raise new safety questions
- The manufacturer meets quality system requirements
- The device's labeling is consistent with its cleared indication
What it does not guarantee
- That the device has undergone independent clinical trials (most 510(k)s rely on bench testing and predicate comparison)
- That the device is safe and effective for uses beyond its cleared indication (off-label use)
- That the device performs identically to the predicate — only that it is "at least as safe and effective"
- That the device has been tested across all Fitzpatrick skin types (this varies by submission)
The FDA has acknowledged this gap. Critics, including some in Congress and the medical community, have noted that the 510(k) standard allows devices to reach the market based on comparison to predicates that may themselves have never undergone rigorous clinical testing — a chain that can stretch back decades.
The 2025–2026 Regulatory Landscape
Several developments are reshaping how aesthetic devices are regulated:
RF microneedling safety communication (October 2025)
The FDA issued a safety communication warning about serious complications — burns, scarring, fat loss, disfigurement, and nerve damage — associated with certain uses of RF microneedling devices. The alert focused on unregulated devices and operators without medical licenses. The American Academy of Dermatology responded that RF microneedling remains safe when performed by board-certified dermatologists using FDA-cleared devices.
New Quality Management System Regulation (February 2026)
The QMSR replaced the decades-old Quality System Regulation (QSR), aligning US requirements with the international standard ISO 13485:2016. This shifts the framework from prescriptive requirements to a risk-based approach. Manufacturers must now maintain robust risk management documentation throughout the device lifecycle.
Cybersecurity requirements
Section 524B of the FD&C Act now requires manufacturers submitting 510(k)s for connected devices to provide cybersecurity documentation, including a software bill of materials (SBOM) and a plan for monitoring post-market vulnerabilities. Many modern aesthetic platforms are software-connected, so this requirement increasingly applies.
New clearances in 2025–2026
- Ultherapy PRIME received FDA clearance in November 2025 for use on the abdomen and arms, expanding beyond its original face/neck/décolleté clearance
- Emsculpt Neo received new clearance in October 2025 for medical rehabilitation beyond aesthetics
- Cutera truFlex received approvals in December 2025 for rehabilitation and therapy applications
Why This Matters for Patients
When a clinic tells you they use "FDA-approved" equipment, that claim is almost certainly inaccurate — and it tells you something about the clinic's attention to regulatory precision. The correct term is FDA-cleared.
More importantly, FDA clearance means the device was found substantially equivalent to something already on the market for a specific intended use. Using the device for a different purpose — treating a different skin condition, using it on a different body area, or combining it with other products — may fall outside the cleared indication. That does not automatically make it unsafe, but it does mean the FDA has not reviewed data for that particular use.
Patients should ask:
- Is the device FDA-cleared for the specific use being proposed? You can search the FDA's 510(k) database by device name or manufacturer.
- Who is performing the procedure? The October 2025 FDA safety communication specifically highlighted risks when procedures are performed by unlicensed operators.
- Has the provider been trained on this specific device? Manufacturer training programs vary widely.
Why This Matters for Providers and Practice Owners
The 510(k) process has strategic implications beyond regulatory compliance:
- Off-label marketing risk. Promoting a device for uses beyond its cleared indication can trigger FDA enforcement. Marketing materials, website copy, and social media posts all receive scrutiny.
- Predicate chain diligence. If a device's predicate has known safety issues, the clearance chain becomes a liability. Some practices request predicate information from manufacturers before purchasing.
- Insurance coverage. Malpractice carriers increasingly ask whether the devices used in a practice are FDA-cleared for the specific procedures performed. Using uncleared devices, or cleared devices for uncleared indications, may affect coverage.
- International market access. A device cleared in the US may still need CE marking under the EU MDR, Health Canada licensing, or other country-specific registrations. The requirements differ substantially across jurisdictions. For providers and manufacturers navigating multi-country device approval and regulatory strategy, MedDeviceGuide offers country-by-country medical device registration guidance covering global approval pathways, RA strategy, and compliance requirements.
The Bottom Line
The 510(k) pathway gets aesthetic devices to market efficiently — about 95% of submissions that reach a decision are cleared. But "cleared" is a comparison standard, not an independent safety finding. It means the device is substantially equivalent to something already legally sold.
For patients, that means asking informed questions about what specific clearance a device holds and who is operating it. For providers, it means understanding the regulatory boundaries of cleared indications, the growing post-market compliance requirements, and the difference between marketing language and what the FDA actually determined.
Sources
- U.S. FDA, "Microneedling Devices," updated October 15, 2025. https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/microneedling-devices
- U.S. FDA, "Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling — FDA Safety Communication," October 15, 2025. https://www.fda.gov/medical-devices/safety-communications/potential-risks-certain-uses-radiofrequency-rf-microneedling-fda-safety-communication
- U.S. FDA, "Dermal Fillers (Soft Tissue Fillers)." https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/dermal-fillers-soft-tissue-fillers
- MedTech Intelligence, "The 510(k) Pathway in 2026: Navigating a Shifting Regulatory and Political Landscape for Medical Devices." https://medtechintelligence.com/feature_article/the-510k-pathway-in-2026-navigating-a-shifting-regulatory-and-political-landscape-for-medical-devices
- Elexes, "FDA 510(k) Submission Updates 2025 — eSTAR, eCopy, Testing." https://www.elexes.com/510k-submission-updates-2025
- Educo Life Sciences, "FDA Pathways Explained: 510(k), De Novo & PMA." https://educolifesciences.com/choosing-the-right-fda-submission-pathway-for-your-medical-device
- Dermascope, "Safety Net: Understanding FDA Approval for Devices." https://www.dermascope.com/safety-net-understanding-fda-approval-for-devices
- PortraitCare, "FDA Approval News for Aesthetics: What to Know for 2026." https://www.portraitcare.com/post/fda-approval-news-for-aesthetics-what-to-know-for-2026
